butylscopolammonium bromide has been researched along with Cancer of Intestines in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, K; Drachenberg, CB; Gao, XM; Heath, J; Khurana, S; Raufman, JP; Shah, N; Shant, J; Shiu, B; Wess, J; Xie, G | 1 |
| Brunier, A; Düber, C; Klose, KJ; Kreitner, KF; Schunk, K | 1 |
2 other study(ies) available for butylscopolammonium bromide and Cancer of Intestines
| Article | Year |
|---|---|
Muscarinic receptor subtype-3 gene ablation and scopolamine butylbromide treatment attenuate small intestinal neoplasia in Apcmin/+ mice.
Topics: Animals; beta Catenin; Butylscopolammonium Bromide; Female; Genes, APC; Intestinal Neoplasms; Intestine, Small; Male; Mice; Mice, Inbred C57BL; Muscarinic Antagonists; Receptor, Muscarinic M3 | 2011 |
[Intestinal contrast imaging in abdominal computed tomography: water or contrast medium?].
Topics: Adolescent; Adult; Aged; Butylscopolammonium Bromide; Child; Contrast Media; Drug Evaluation; Female; Glucagon; Humans; Intestinal Neoplasms; Intestines; Iothalamic Acid; Male; Middle Aged; Radiography, Abdominal; Tomography, X-Ray Computed; Water | 1991 |